All Blogs

Oct 23, 2018

Novartis comes up with an answer for breast cancer with PI3K drug alpelisib Novartis comes up with an answer with its recent data on BYL719 (alpelisib) in combination with fulvestrant. Their alpha-specific drug for PIK3CA mutated HR+/HER2- advanced breast cancer, BYL719 plus fulvestrant nearly doubled the progressio...

Oct 22, 2018

[caption id="attachment_3465" align="alignnone" width="800"] INSIGHTS ON TRIPLE NEGATIVE BREAST CANCER[/caption]   To know more about TRIPLE NEGATIVE BREAST CANCER request for sample pages: https://www.delveinsight.com/dev-sample.php?form_name=Triple-Negative-Breast-Cancer-(TNBC)---Market-Insight,-Epidemi...

Oct 18, 2018

Novartis signs USD 2.1Billion for Endocyte acquisition Novartis has inked USD 2.1 billion agreement to takeover Endocyte. Endocyte, a biopharmaceutical company, headquartered in Indiana, licensed the cancer drug that catches Novartis’ eye for USD 12 million. Endocyte was in the stagnation when it held its recovery h...

Oct 17, 2018

Pharmaceutical companies will disclose the price of medicines in television advertisements to consumers. The step is taken up by the Trump administration to control rampant spending on drugs. A major change taken up by Health and Human Services Secretary, Alex Azar and drafted as a new federal rule, drug manufacture...

Oct 16, 2018

FDA approves expanded label for Xarelto of Johnson & Johnson The Food and Drug Administration permitted labelling of blood thinner, Xarelto of Johnson & Johnson, as it can decrease the risk of major cardiovascular events in patients with peripheral artery disease or chronic coronary artery disease (CAD or P...

Oct 12, 2018

Gene Therapy is now touted as a new revolution for cancer treatment. If the list of new cancer treatment methodologies is traversed, then the end seems to be farther and farther away. As a sequel to the relentless efforts by researchers across the world to formulate therapies better than the existing ones, new prosp...

Oct 11, 2018

Cytosen Therapeutics and KBI Biopharma pair up to manufacture NK cells and Nanoparticles  CytoSen Therapeutics and KBI Biopharma paired up to manufacture therapeutic Natural Killer Cell by using a closed system manufacturing process. According to the initial collaboration, KBI will be subjected to manufactur...

Oct 11, 2018

Streamlined solutions provided by Cognitive Clinical Trials (CCT) related to the treatment and prevention of Alzheimer’s disease Congnitive Clinical Trials (CCT) has introduced a new research model that prevail over the top obstacles being faced by the researchers related to the treatment and prevention of Alzheime...

Oct 11, 2018

SNAPSHOTS: Copiktra receives FDA approval for CLL and FL, Relief for tazemetostat developers after FDA lifted partial clinical hold, Conference highlights from 19th WCLC The United States Food and Drug Administration (USFDA) has granted approval to Verastem’s Copiktra (duvelisib), for the treatment of patients with...

Oct 11, 2018

Orchard files for USD173 Million IPO to run pivotal gene therapy trials Orchard Therapeutics, Transatlantic biotech, has filed to raise USD 173 million in an IPO. This will lead it to take three gene therapies through the clinic. Orchard recognised itself as one of the broadest clinical-phase gene therapy pipelines ...